AstraZeneca's Zomig nasal spray good for cluster headache
Results from a new pooled data analysis presented at the European Headache and Migraine Trust International Congress 2008 today show that zolmitriptan (Anglo-Swedish drug major AstraZeneca's Zomig) nasal spray provided fast and efficacious relief in the treatment of episodic and chronic cluster headache. The data shows that zolmitriptan nasal spray provided significant relief from cluster headache at 30 minutes - this maybe of real significance for patients whose current treatment options (oxygen inhalation, self administered sumatriptan injection or a combination of both) are limited due to inconvenience of use.
Zolmitriptan nasal spray has recently been approved in the Netherlands, Denmark and Germany for the acute treatment of cluster headache, but is not yet licensed in the UK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze